Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention

Villarreal‐Garza, Cynthia; Mesa-Chavez, Fernanda; Garza-Ledezma, Ma Ria Alejandra; Peña-Curiel, Omar; Martínez-Cannon, Bertha Alejandra; Canavati-Marcos, Mauricio; Cardona‐Huerta, Servando

doi:10.1007/s10549-020-05968-w

Cited by 11 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the most important influence is the chemotherapeutic agent. In accordance with previously published studies [ 9 , [12] , [13] , [14] ], we observed that SC was more effective in patients receiving taxane monotherapy than in patients receiving an anthracycline-taxane-based regimen. Using the patients’ evaluation, 50% of patients with taxane monotherapy had grade 1 alopecia compared to 17.2% of patients with an anthracycline-taxane-based regimen.…”

Section: Discussionsupporting

confidence: 93%

“…Initial studies on SC were conducted primarily with taxane- and only rarely anthracycline-based chemotherapy [ 9 ]. A high efficacy of SC was previously demonstrated for chemotherapy containing taxanes only; however, this does not reflect clinical reality considering that most chemotherapy regimens contain two or more cytostatic agents [ 9 , [12] , [13] , [14] ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study

Brunner¹,

Emmelheinz²,

Kofler

et al. 2022

The Breast

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study

Brunner¹,

Emmelheinz²,

Kofler

et al. 2022

The Breast

View full text Add to dashboard Cite

“…Scalp cooling was well tolerated with high median VAS scores. Our results are in accordance with the results of the other scalp cooling studies with a shorter PICT in 3 weekly docetaxel-containing chemotherapy [ 12 , 15 ] and results of scalp cooling in taxane-based chemotherapy [ 3 , 6 , 18 ]. In the docetaxel PICT study 61% of the patients were male, whereas in our study predominantly female patients (95%) participated.…”

Section: Discussionsupporting

confidence: 92%

Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia — a randomized controlled trial

Lugtenberg

Hurk

Smorenburg

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose Scalp cooling can prevent chemotherapy-induced alopecia (CIA). Previously, the post-infusion cooling time (PICT) could be successfully reduced in docetaxel-treated patients from 90 to 45 and 20 min. Therefore, it seems plausible that the PICT can be shortened for paclitaxel-treated patients as well. Methods Patients treated with weekly paclitaxel were included in this multi-centre trial and randomly assigned to a PICT of 45 or 20 min. The results were compared to a standard PICT of 90 min, derived from prospective collected data from the Dutch Scalp Cooling Registry. The primary endpoint was the percentage of patients who decide to not wear a wig or head covering. Secondary endpoints were the degree of CIA assessed with the Dean scale for assessment of hair loss; alopecia graded according to NCI CTC toxicity version 4.03 (CTCAE4.03); tolerance of scalp cooling and perceived distress of CIA. Results Ninety-one patients were enrolled in this study; 74 patients were evaluable for hair loss. Hair preservation was successful in 27 patients (75%) with a PICT of 45 min and in 31 patients (82%) with a PICT of 20 min. There was no difference in success rate with the standard PICT of 90 min (85%, p = 0.29). Similar success rates were seen when using the Dean scale and CTCAE assessment, with no differences between groups (p = 0.12 and p = 0.38). Conclusions A 20 min PICT is as effective as 45 and 90 min to prevent weekly paclitaxel-induced alopecia and should be the new standard of care. Trial register ClinicalTrials.gov Identifier: NCT03266185.

show abstract

“…In our analysis, no difference in terms of success rate according to dose-dense or standard schedule was reported (64.4% versus 69.2%, p = 0.557). Similarly, a recent single-center retrospective study reported a satisfactory hair prevention rate of 60.0% with dose-dense regimens; however, only 15 out of 80 patients included in this study received a dose-dense schedule [ 23 ]. This aspect is relevant for clinical practice given the important role of the chemotherapy dose dense schedule in increasing the BC outcome [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer

Carbognin

Accetta

Giorgio³

et al. 2022

Current Oncology

View full text Add to dashboard Cite

The prevention of chemotherapy-induced alopecia still represents an urgent need for every day clinical practice. In this regard, this prospective single-center study included breast cancer (BC) patients who underwent a scalp cooling device (Dignicap®) during (neo)adjuvant chemotherapy with the aim to evaluate the efficacy and safety of this device in preventing alopecia. One hundred and seventy-eight patients (median age 43 years) were enrolled. The chemotherapy regimen included anthracycline and taxane-based chemotherapy (68.1%), docetaxel and cyclophosphamide (25.8%), anthracycline and taxane-based plus carboplatin (3.9%), and paclitaxel alone (2.2%). In 25.3% of cases, a dose dense schedule was used. Overall, the success rate was 68.0%: 100% in paclitaxel alone, 87.0% in docetaxel-cyclophosphamide, 59.5% in anthracycline and taxane, and 71.4% in the sequential regimen plus carboplatin group (anthracycline and taxane-based chemotherapy versus taxane-based chemotherapy, p ≤ 001. No difference in terms of hair preservation between dose-dense or standard schedule was found (p = 0.557). Early discontinuation of the scalp cooling was observed in 50 patients (28.1%). Although 138 patients (77.5%) experienced adverse events, 70.2% of patients were satisfied with this device. In conclusion, this large prospective study confirmed the helpful effect of the scalp cooling system in preventing alopecia in BC patients also undergoing sequential anthracyclines and taxane-based chemotherapy.

show abstract

Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention

Cited by 11 publications

References 19 publications

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study

Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia — a randomized controlled trial

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer

Contact Info

Product

Resources

About